{
    "ticker": "SRPT",
    "name": "Sarepta Therapeutics, Inc.",
    "description": "Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative RNA-targeted therapeutics for the treatment of rare diseases, particularly those affecting muscle health. Founded in 1980 and based in Cambridge, Massachusetts, Sarepta aims to transform the lives of patients with serious and life-threatening diseases through its proprietary technologies. The company is best known for its work in the field of Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration. Sarepta's lead product candidate, Eteplirsen, has garnered significant attention as a potential treatment for DMD, utilizing exon-skipping technology to address the underlying genetic cause of the disease. In addition to its focus on DMD, Sarepta is expanding its pipeline to include therapies for other genetic diseases, leveraging its expertise in gene therapy and RNA-based medicine. With a commitment to patient-centric research and development, Sarepta actively engages with the DMD community and conducts clinical trials to bring innovative solutions to patients in need. The company is dedicated to advancing the science of genetic medicine and has positioned itself as a leader in the development of transformative therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "1980",
    "website": "https://www.sareptatherapeutics.com",
    "ceo": "Doug Ingram",
    "social_media": {
        "twitter": "https://twitter.com/Sarepta",
        "linkedin": "https://www.linkedin.com/company/sarepta-therapeutics/"
    },
    "investor_relations": "https://investors.sareptatherapeutics.com",
    "key_executives": [
        {
            "name": "Doug Ingram",
            "position": "CEO"
        },
        {
            "name": "Sharon H. L. K. H. M. Keck",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Eteplirsen",
                "Golodirsen",
                "Viltolarsen"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sarepta Therapeutics, Inc. | Pioneering RNA-targeted Therapies",
        "meta_description": "Explore Sarepta Therapeutics, Inc., a leader in RNA-targeted therapies for rare diseases, particularly Duchenne muscular dystrophy. Learn about their innovative treatments and commitment to patient care.",
        "keywords": [
            "Sarepta Therapeutics",
            "Duchenne Muscular Dystrophy",
            "RNA-targeted therapies",
            "Eteplirsen",
            "Biotechnology",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Sarepta Therapeutics known for?",
            "answer": "Sarepta Therapeutics is known for its RNA-targeted therapies, particularly for treating Duchenne muscular dystrophy."
        },
        {
            "question": "Who is the CEO of Sarepta Therapeutics?",
            "answer": "Doug Ingram is the CEO of Sarepta Therapeutics, Inc."
        },
        {
            "question": "Where is Sarepta headquartered?",
            "answer": "Sarepta is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are Sarepta's main products?",
            "answer": "Sarepta's main products include Eteplirsen, Golodirsen, and Viltolarsen, which are aimed at treating DMD."
        },
        {
            "question": "When was Sarepta founded?",
            "answer": "Sarepta was founded in 1980."
        }
    ],
    "competitors": [
        "PTCT",
        "AVDL",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "VRTX"
    ]
}